Selling the assets to Italy’s GVS should help Haemonetics improve its revenue growth and profit margins, analysts said.
By using pre-determined change control plans, manufacturers can update AI-enabled devices without filing an additional FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback